The dry eye syndrome market size has grown strongly in recent years. It will grow from $3.92 billion in 2024 to $4.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to healthcare accessibility, evolving treatment options, medications and health conditions, hormonal changes, ocular surgery impact.
The dry eye syndrome market size is expected to see strong growth in the next few years. It will grow to $5.63 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to aging population demographics, increasing screen usage, shift in lifestyle habits, healthcare awareness and accessibility, ocular surgery trends, development of novel therapies. Major trends in the forecast period include holistic approach to eye health, integration of ai in eye care, telemedicine and remote consultations, personalized medicine approach, rise in awareness and education.
The anticipated growth of the dry eye syndrome market is expected to be driven by the increasing prevalence of dry eye syndrome. This condition occurs when the eyes do not produce enough tears, and products and medications designed for dry eye syndrome aim to provide lubrication and moisture, boost tear production, enhance tear quality, reduce inflammation, and protect the ocular surface. For instance, a survey conducted by Eyes On Eyecare in March 2022 revealed that 35 million Americans were projected to experience dry eye disease (DED) in 2022, with a continued increase in frequency. Additionally, a meta-analysis of three US studies in 2022, according to UpToDate Inc., reported an 8.1% pooled prevalence of dry eye. Hence, the rising prevalence of dry eye syndrome is a significant driver for the market.
The growth of the dry eye syndrome market is the expanding aging population. This demographic trend, characterized by a rising proportion of elderly individuals, creates an increased demand for effective treatments and solutions for conditions such as dry eye syndrome. Globally, the World Health Organization projects that by 2030, 1 in 6 people will be 60 or older, and this age group will double to 2.1 billion by 2050. In the UK, data from the UK Parliament's House of Commons Library indicates that by 2043, 24% of the total population (17.4 million people) will consist of seniors. Consequently, the growing aging population becomes a driving force for the dry eye syndrome market.
Product innovation stands out as a prominent trend, with major companies focusing on the development of innovative solutions to maintain their market position. For example, in May 2023, Entod Pharmaceuticals Ltd., an India-based company, introduced Cyclotears eye drops, specifically designed for treating dry eye disease. This pioneering product incorporates self-emulsifying drug delivery system (SEDDS) technology, enhancing the delivery of poorly water-soluble drugs to the ocular region. Cyclotears eye drops utilize cyclodextrin to enhance stability and retention time of the tear film on the eye surface. Some highlighted features include a novel active ingredient, improved retention time, a lubricating effect, and being safe and preservative-free.
Major players in the dry eye syndrome market are directing their efforts towards launching innovative products to address the increasing demand for preservative-free eye drops. An example is Systane, with its Systane Complete Preservative-Free Lubricant Eye Drops added to its innovative portfolio of dry eye products. Alcon, a Switzerland-based ophthalmology company, introduced these eye drops in January 2022 to cater to individuals experiencing dry eyes, a condition resulting from insufficient tear production or rapid tear evaporation. Systane Complete Preservative-Free Lubricant Eye Drops aim to alleviate various dry eye symptoms, providing relief, protection, and hydration.
In June 2022, Novartis AG, a Switzerland-based pharmaceutical corporation, completed the acquisition of Kedalion Therapeutics for an undisclosed amount. This strategic move positions Novartis AG to deliver customer- and patient-centric ophthalmic advancements, particularly for dry eye syndrome, and strengthens its leadership in the rapidly growing ophthalmology market. Kedalion Therapeutics, a US-based clinical-stage ophthalmic drug company, offers a range of products and preventive services for dry eye syndrome.
Major companies operating in the dry eye syndrome market include Allergan plc, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Santendo Pharmaceutical Co. Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Alcon Vision LLC, Akorn Operating Company LLC, Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., AbbVie Inc., I-MED Pharma Inc., AFT Pharmaceuticals, Horus Pharma, Mitotech, Novaliq GmbH, OASIS Medical, Prestige Consumer Healthcare, VISUfarma, Alimera Science, Kala Pharmaceuticals Inc., Nicox S.A., EyeGate Pharmaceuticals Inc., ReVision Therapeutics Inc., Itear Medical.
North America was the largest region in the dry eye syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global dry eye syndrome market report during the forecast period. The regions covered in the dry eye syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dry eye syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Dry eye syndrome, also known as dry eye illness, is a prevalent condition characterized by insufficient tear production or the generation of poor-quality tears. The condition manifests when the eyes fail to produce an adequate amount of tears, leading to discomfort, irritation, and inflammation.
Products designed to address dry eye syndrome include liquid drops, gel formulations, liquid wipes, eye ointments, and other related solutions. Liquid eye drops, specifically, are fluid formulations applied directly to the eyes to alleviate dryness, provide moisture, and offer lubrication. These drops encompass a variety of treatments, ranging from corticosteroids to artificial tears, oral omega supplements, and lubricating agents. These products are available through both offline and online channels and are employed in the treatment of evaporative and aqueous diseases. They find application in diverse settings, including hospitals, clinics, medical laboratories, and other healthcare facilities.
The dry eye syndrome market research report is one of a series of new reports that provides dry eye syndrome market statistics, including dry eye syndrome industry global market size, regional shares, competitors with a dry eye syndrome market share, detailed dry eye syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the dry eye syndrome industry. This dry eye syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dry eye syndrome market includes revenues earned by entities by providing services such as dry eye diagnosis, treatment of dry eye syndrome, prescribed medications, antibiotics, humidifiers, and protective eyewear. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The dry eye syndrome market size is expected to see strong growth in the next few years. It will grow to $5.63 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to aging population demographics, increasing screen usage, shift in lifestyle habits, healthcare awareness and accessibility, ocular surgery trends, development of novel therapies. Major trends in the forecast period include holistic approach to eye health, integration of ai in eye care, telemedicine and remote consultations, personalized medicine approach, rise in awareness and education.
The anticipated growth of the dry eye syndrome market is expected to be driven by the increasing prevalence of dry eye syndrome. This condition occurs when the eyes do not produce enough tears, and products and medications designed for dry eye syndrome aim to provide lubrication and moisture, boost tear production, enhance tear quality, reduce inflammation, and protect the ocular surface. For instance, a survey conducted by Eyes On Eyecare in March 2022 revealed that 35 million Americans were projected to experience dry eye disease (DED) in 2022, with a continued increase in frequency. Additionally, a meta-analysis of three US studies in 2022, according to UpToDate Inc., reported an 8.1% pooled prevalence of dry eye. Hence, the rising prevalence of dry eye syndrome is a significant driver for the market.
The growth of the dry eye syndrome market is the expanding aging population. This demographic trend, characterized by a rising proportion of elderly individuals, creates an increased demand for effective treatments and solutions for conditions such as dry eye syndrome. Globally, the World Health Organization projects that by 2030, 1 in 6 people will be 60 or older, and this age group will double to 2.1 billion by 2050. In the UK, data from the UK Parliament's House of Commons Library indicates that by 2043, 24% of the total population (17.4 million people) will consist of seniors. Consequently, the growing aging population becomes a driving force for the dry eye syndrome market.
Product innovation stands out as a prominent trend, with major companies focusing on the development of innovative solutions to maintain their market position. For example, in May 2023, Entod Pharmaceuticals Ltd., an India-based company, introduced Cyclotears eye drops, specifically designed for treating dry eye disease. This pioneering product incorporates self-emulsifying drug delivery system (SEDDS) technology, enhancing the delivery of poorly water-soluble drugs to the ocular region. Cyclotears eye drops utilize cyclodextrin to enhance stability and retention time of the tear film on the eye surface. Some highlighted features include a novel active ingredient, improved retention time, a lubricating effect, and being safe and preservative-free.
Major players in the dry eye syndrome market are directing their efforts towards launching innovative products to address the increasing demand for preservative-free eye drops. An example is Systane, with its Systane Complete Preservative-Free Lubricant Eye Drops added to its innovative portfolio of dry eye products. Alcon, a Switzerland-based ophthalmology company, introduced these eye drops in January 2022 to cater to individuals experiencing dry eyes, a condition resulting from insufficient tear production or rapid tear evaporation. Systane Complete Preservative-Free Lubricant Eye Drops aim to alleviate various dry eye symptoms, providing relief, protection, and hydration.
In June 2022, Novartis AG, a Switzerland-based pharmaceutical corporation, completed the acquisition of Kedalion Therapeutics for an undisclosed amount. This strategic move positions Novartis AG to deliver customer- and patient-centric ophthalmic advancements, particularly for dry eye syndrome, and strengthens its leadership in the rapidly growing ophthalmology market. Kedalion Therapeutics, a US-based clinical-stage ophthalmic drug company, offers a range of products and preventive services for dry eye syndrome.
Major companies operating in the dry eye syndrome market include Allergan plc, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Santendo Pharmaceutical Co. Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Alcon Vision LLC, Akorn Operating Company LLC, Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., AbbVie Inc., I-MED Pharma Inc., AFT Pharmaceuticals, Horus Pharma, Mitotech, Novaliq GmbH, OASIS Medical, Prestige Consumer Healthcare, VISUfarma, Alimera Science, Kala Pharmaceuticals Inc., Nicox S.A., EyeGate Pharmaceuticals Inc., ReVision Therapeutics Inc., Itear Medical.
North America was the largest region in the dry eye syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global dry eye syndrome market report during the forecast period. The regions covered in the dry eye syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dry eye syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Dry eye syndrome, also known as dry eye illness, is a prevalent condition characterized by insufficient tear production or the generation of poor-quality tears. The condition manifests when the eyes fail to produce an adequate amount of tears, leading to discomfort, irritation, and inflammation.
Products designed to address dry eye syndrome include liquid drops, gel formulations, liquid wipes, eye ointments, and other related solutions. Liquid eye drops, specifically, are fluid formulations applied directly to the eyes to alleviate dryness, provide moisture, and offer lubrication. These drops encompass a variety of treatments, ranging from corticosteroids to artificial tears, oral omega supplements, and lubricating agents. These products are available through both offline and online channels and are employed in the treatment of evaporative and aqueous diseases. They find application in diverse settings, including hospitals, clinics, medical laboratories, and other healthcare facilities.
The dry eye syndrome market research report is one of a series of new reports that provides dry eye syndrome market statistics, including dry eye syndrome industry global market size, regional shares, competitors with a dry eye syndrome market share, detailed dry eye syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the dry eye syndrome industry. This dry eye syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dry eye syndrome market includes revenues earned by entities by providing services such as dry eye diagnosis, treatment of dry eye syndrome, prescribed medications, antibiotics, humidifiers, and protective eyewear. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Dry Eye Syndrome Market Characteristics3. Dry Eye Syndrome Market Trends and Strategies4. Dry Eye Syndrome Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Dry Eye Syndrome Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Dry Eye Syndrome Market34. Recent Developments in the Dry Eye Syndrome Market
5. Global Dry Eye Syndrome Growth Analysis and Strategic Analysis Framework
6. Dry Eye Syndrome Market Segmentation
7. Dry Eye Syndrome Market Regional and Country Analysis
8. Asia-Pacific Dry Eye Syndrome Market
9. China Dry Eye Syndrome Market
10. India Dry Eye Syndrome Market
11. Japan Dry Eye Syndrome Market
12. Australia Dry Eye Syndrome Market
13. Indonesia Dry Eye Syndrome Market
14. South Korea Dry Eye Syndrome Market
15. Western Europe Dry Eye Syndrome Market
16. UK Dry Eye Syndrome Market
17. Germany Dry Eye Syndrome Market
18. France Dry Eye Syndrome Market
19. Italy Dry Eye Syndrome Market
20. Spain Dry Eye Syndrome Market
21. Eastern Europe Dry Eye Syndrome Market
22. Russia Dry Eye Syndrome Market
23. North America Dry Eye Syndrome Market
24. USA Dry Eye Syndrome Market
25. Canada Dry Eye Syndrome Market
26. South America Dry Eye Syndrome Market
27. Brazil Dry Eye Syndrome Market
28. Middle East Dry Eye Syndrome Market
29. Africa Dry Eye Syndrome Market
30. Dry Eye Syndrome Market Competitive Landscape and Company Profiles
31. Dry Eye Syndrome Market Other Major and Innovative Companies
35. Dry Eye Syndrome Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Dry Eye Syndrome Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on dry eye syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dry eye syndrome? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dry eye syndrome market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Liquid Drops; Gel; Liquid Wipes; Eye Ointment; Other Products2) By Treatment: Corticosteroids; Artificial Tears; Oral Omega Supplements; Lubricating Agent; Other Treatments
3) By Disease Type: Evaporative; Aqueous
4) By Distribution Channel: Offline; Online
5) By Application: Hospitals and Clinics; Medical Laboratories; Other Applications
Subsegments:
1) By Liquid Drops: Preservative-Free Drops; Preserved Liquid Drops; Antibiotic-Infused Drops2) By Gel: Long-Lasting Gels; Hydrogel Formulations
3) By Liquid Wipes: Pre-Moistened Wipes; Anti-Bacterial Wipes
4) By Eye Ointment: Night-Time Ointments; Therapeutic Ointments
5) By Other Products: Eye Masks; Contact Lens Solutions; Nutritional Supplements
Key Companies Mentioned: Allergan plc; Novartis AG; Otsuka Pharmaceutical Co. Ltd.; Santendo Pharmaceutical Co. Ltd.; Sentiss Pharma Pvt. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Allergan plc
- Novartis AG
- Otsuka Pharmaceutical Co. Ltd.
- Santendo Pharmaceutical Co. Ltd.
- Sentiss Pharma Pvt. Ltd.
- Johnson & Johnson
- Alcon Vision LLC
- Akorn Operating Company LLC
- Sun Pharmaceutical Industries Ltd.
- Bausch Health Companies Inc.
- AbbVie Inc.
- I-MED Pharma Inc.
- AFT Pharmaceuticals
- Horus Pharma
- Mitotech
- Novaliq GmbH
- OASIS Medical
- Prestige Consumer Healthcare
- VISUfarma
- Alimera Science
- Kala Pharmaceuticals Inc.
- Nicox S.A.
- EyeGate Pharmaceuticals Inc.
- ReVision Therapeutics Inc.
- Itear Medical
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 4.21 Billion |
| Forecasted Market Value ( USD | $ 5.63 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
